| Trial Identifier: | 208850 |
| Sponsor: | GlaxoSmithKline |
| Start Date: | March 2019 |
| Primary Completion Date: | April 2024 |
| Study Completion Date: | January 2026 |
| Condition: | Cancer - Other |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| Country | Location |
|---|---|
| AUSTRALIA, VIC | Melbourne, VIC, AUSTRALIA, 3000 |
| CANADA, ON | Toronto, ON, CANADA, M5G 1Z9 |
| FRANCE | Bordeaux, FRANCE, 33076 |
| FRANCE | Villejuif cedex, FRANCE, 94805 |
| JAPAN | Tokyo, JAPAN, 104-0045 |
| JAPAN | Tokyo, JAPAN, 135-8550 |
| KOREA,_REPUBLIC_OF | SEOUL, KOREA,_REPUBLIC_OF, 03080 |
| NETHERLANDS | AMSTERDAM, NETHERLANDS, 1066 CX |
| NETHERLANDS | AMSTERDAM, NETHERLANDS, 1081 HV |
| SPAIN | Madrid, SPAIN, 28050 |
| SPAIN | Madrid, SPAIN, 28040 |
| UNITED_STATES, TX | Houston, TX, UNITED_STATES, 77030 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2026 Pharma Intelligence UK Limited (Citeline), a Norstella company